How do you onboard a new principal investigator?

Onboard a new principal investigator by filing evidence of qualifications, training them on the protocol, Investigator's Brochure and product, and confirming they have time, staff and facilities for the trial (ICH E6(R3) 2.2.2).

Then have them sign the protocol agreement and review the delegation record they will oversee.

Qualifications and paperwork

  • A current CV and evidence of education, training and experience (ICH E6(R3) 2.1.1).
  • A current GCP training certificate, and any license the role requires locally.
  • For a US drug study under an IND, a signed Form FDA 1572 listing the subinvestigators (21 CFR 312.53(c)).
  • The signed protocol or an alternative contract with the sponsor (ICH E6(R3) 2.5.1), and any financial disclosure the sponsor needs.

What the new investigator must know

  • The appropriate use of the investigational product as described in the protocol and the current Investigator's Brochure (ICH E6(R3) 2.1.2).
  • That medical decisions stay with a qualified physician, or other qualified professional where local rules allow, who is an investigator or subinvestigator (ICH E6(R3) 2.7.1(a)).
  • Their duty to report serious adverse events to the sponsor immediately (ICH E6(R3) 2.7.2(b)).
  • Their general duties under US rules: conduct the study by the signed statement and the plan, protect participants, and control the drug (21 CFR 312.60).

Delegation and oversight

The investigator may delegate trial tasks but keeps ultimate responsibility and should oversee delegated work in proportion to its importance and risk (ICH E6(R3) 2.3.1). A new investigator should review and sign the delegation record for the existing team, confirm each person's training, and agree how they will oversee the work: regular review of safety events, eligibility decisions and deviations.

When the investigator changes mid-study

A change of principal investigator usually needs IRB or IEC notification and sponsor action, and for a US IND study a new Form FDA 1572 (21 CFR 312.53(c)). Plan a handover meeting, update the delegation record, and keep the outgoing investigator's records in the site file.

Questions people also ask

Does a new principal investigator need GCP training?

Yes in practice. ICH E6(R3) expects qualification by education, training and experience with evidence of it (ICH E6(R3) 2.1.1), and sponsors usually ask for a current GCP certificate.

Can a principal investigator delegate everything?

No. Tasks can be delegated, but responsibility and oversight cannot (ICH E6(R3) 2.3.1), and trial-related medical decisions stay with a qualified investigator (ICH E6(R3) 2.7.1(a)).

Who signs the Form FDA 1572?

The investigator, before taking part in a US IND study; the sponsor collects it (21 CFR 312.53(c)).

What should a first-time investigator read first?

The protocol, the Investigator's Brochure and the investigator section of ICH E6(R3), then the site's SOPs for safety reporting and delegation.

Primary sources

  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
  • 21 CFR 312.53: Selecting investigators and monitors (eCFR): https://www.ecfr.gov/current/title-21/section-312.53
  • 21 CFR 312.60: General responsibilities of investigators (eCFR): https://www.ecfr.gov/current/title-21/section-312.60
  • Investigator Responsibilities: Protecting the Rights, Safety, and Welfare of Study Subjects, guidance (FDA): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects

Last reviewed

2026-11-14